EVOTF (Evotec SE) Asset Impairment Charge : $0.0 Mil (TTM As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is Evotec SE Asset Impairment Charge?

Evotec SE's Asset Impairment Charge for the three months ended in Sep. 2024 was $0.0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2024 was $0.0 Mil.

Evotec SE Asset Impairment Charge Historical Data

The historical data trend for Evotec SE's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Asset Impairment Charge Chart

Evotec SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Get a 7-Day Free Trial

13.24

3.95

0.77

5.47

Evotec SE Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Evotec SE Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

Evotec SE Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Evotec SE's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Evotec SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (OTCPK:EVOTF) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

EVO:USA 1EVT:Italy EVTd:UK 0IRF:UK EVT:Germany EVT:Germany EVT:Germany EVT:Germany EVTA:Germany EVT:Bulgaria EVT:Austria

Address

Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419

Website

https://www.evotec.com

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.